Editorial: can we get more clinical benefit from thiopurine metabolite testing? - Wikidata - awgldk - TriplyDB

Editorial: can we get more clinical benefit from thiopurine metabolite testing?

Editorial: can we get more clinical benefit from thiopurine metabolite testing?

http://www.wikidata.org/entity/Q48223472

about

Editorial: can we get more clinical benefit from thiopurine metabolite testing?

http://www.wikidata.org/entity/Q48223472

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Editorial: can we get more clinical benefit from thiopurine metabolite testing?

@en

Editorial: can we get more clinical benefit from thiopurine metabolite testing?

@nl

type

label

Editorial: can we get more clinical benefit from thiopurine metabolite testing?

@en

Editorial: can we get more clinical benefit from thiopurine metabolite testing?

@nl

prefLabel

Editorial: can we get more clinical benefit from thiopurine metabolite testing?

@en

Editorial: can we get more clinical benefit from thiopurine metabolite testing?

@nl

P1433

Q48223472-C2CFFFE2-006F-4A27-A481-58E6F7C62D09

P1476

Q48223472-09F36A65-62F0-4BC3-9D99-CF49F98ACD02

P2093

Q48223472-37CE4DD0-F5D8-458D-8FB9-83AE72D88A7B

P2860

Q48223472-07C85577-CFEA-43C4-B55F-A48B793C89A6

Q48223472-0E869883-E963-43FA-B785-8C0D0A4CAF33

Q48223472-22BC0572-296F-405A-98EE-2ADF80304094

Q48223472-576A18F2-D2E5-43EC-9BB9-BBE31EF9B010

Q48223472-78AE6A4D-088F-422B-8826-8B61AC7B5ED3

Q48223472-8F0EBAFD-6A89-4B1D-BE0B-BE48309C3DF0

Q48223472-A5BB0A88-DDA0-48C4-A8A0-1C60ECBB0C87

Q48223472-D9C1B7A4-4DF0-4B09-8CC2-26E547E9D7DF

Q48223472-DD2E07AE-BD7B-441B-8FD1-BAAE5397B433

P304

Q48223472-5BC4CC5C-BDF6-4818-BE62-648D9D94639D

P31

Q48223472-211e95f1-e0cf-44c3-99eb-e6b896b065eb

Q48223472-E72FB75D-D3D5-4307-82FF-C0932E7A919E

P356

Q48223472-04D7D508-0D67-4477-AB91-44CBBCB7E59A

P407

Q48223472-0E1AA185-0913-4842-80C4-1DF2EC1769AD

P433

Q48223472-59B939ED-E24B-4FC6-B134-B6417739E4DF

P478

Q48223472-0A958484-743C-47FA-B2AE-C8E7DB083D32

P50

Q48223472-931B84B0-069A-4B97-9143-6105D57E3A19

P577

Q48223472-21BCEF66-F604-42DB-9DE0-05027478184C

P698

Q48223472-8ED7EBC2-4995-4F70-8D3B-ADE7AFE259A5

P356

P1433

Alimentary Pharmacology & Therapeutics

P1476

Editorial: can we get more clinical benefit from thiopurine metabolite testing?

@en

P2093

A G Fraser

http://www.w3.org/2001/XMLSchema#string

P2860

Thiopurine-induced liver injury in patients with inflammatory bowel disease: a systematic review.

Review article: recent advances in pharmacogenetics and pharmacokinetics for safe and effective thiopurine therapy in inflammatory bowel disease.

Routinely Established Skewed Thiopurine Metabolism Leads to a Strikingly High Rate of Early Therapeutic Failure in Patients With Inflammatory Bowel Disease.

Incidence of nodular regenerative hyperplasia in inflammatory bowel disease patients treated with azathioprine.

Mercaptopurine rescue after azathioprine-induced liver injury in inflammatory bowel disease.

Safety and effectiveness of long-term allopurinol-thiopurine maintenance treatment in inflammatory bowel disease.

Early prediction of thiopurine-induced hepatotoxicity in inflammatory bowel disease.

Optimising outcome on thiopurines in inflammatory bowel disease by co-prescription of allopurinol.

Early Assessment of Thiopurine Metabolites Identifies Patients at Risk of Thiopurine-induced Leukopenia in Inflammatory Bowel Disease.

P304

857-858

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/APT.13942

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

45

http://www.w3.org/2001/XMLSchema#string

P50

P577

2017-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28211629

http://www.w3.org/2001/XMLSchema#string